SCHEMBL31419754

SCHEMBL31419754

N[C@@H]1CCC[C@H](C(=O)Nc2nc3c(F)cc(F)cc3s2)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 9/20 0.72
▸ NPC1 O15118 9/20 0.72
▸ CHKA P35790 1/20 0.51
▸ MAPT P10636 5/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ PKM P14618 2/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ LMNA P02545 2/20 0.48
▸ AGTR1 P30556 1/20 0.48
▸ OPRK1 P41145 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ POLB P06746 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ GAA P10253 1/20 0.44
▸ ABL1 P00519 2/20 0.44
▸ TNF P01375 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30944356 0.87 RAB9A (0.72) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL30944422 0.86 RAB9A (0.88) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL28529297 0.86 RAB9A (0.88) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL30944411 0.86 RAB9A (0.88) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL30944350 0.86 RAB9A (0.88) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL24071962 0.86 RAB9A (0.88) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL28522078 0.86 RAB9A (0.88) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL30944368 0.84 RAB9A (0.76) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL31419737 0.82 RAB9A (0.65) RAB9ANPC1CHKAMAPTALDH1A1
SCHEMBL24071463 0.81 NPC1 (0.73) RAB9ANPC1CHKAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092030-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2025-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092030-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A PDE2A, GUCY1A1, GCGR RAB9A 960/4885NPC1 1065/4885CHKA 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback